653 related articles for article (PubMed ID: 15645139)
1. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
[TBL] [Abstract][Full Text] [Related]
4. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
Indrová M; Bubeník J; Mikysková R; Vonka V; Smahel M; Zák R; Símová J; Bieblová J; Mendoza L; Jandlová T
Int J Oncol; 2002 Mar; 20(3):643-6. PubMed ID: 11836582
[TBL] [Abstract][Full Text] [Related]
5. Local IFN-gamma therapy of HPV16-associated tumours.
Mikysková R; Bieblová J; Símová J; Indrová M; Jandlová T; Vonka V; Smahel M; Bubeník J; Mendoza L
Folia Biol (Praha); 2003; 49(1):26-32. PubMed ID: 12630665
[TBL] [Abstract][Full Text] [Related]
6. MHC class I+ and class I- HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.
Símová J; Mikysková R; Vonka V; Bieblová J; Bubeník J; Jandlová T
Folia Biol (Praha); 2003; 49(6):230-4. PubMed ID: 14748438
[TBL] [Abstract][Full Text] [Related]
7. NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours.
Indrová M; Símová J; Bieblová J; Bubeník J; Reinis M
Oncol Rep; 2011 Jan; 25(1):281-8. PubMed ID: 21109988
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors.
Indrová M; Mikysková R; Jandlová T; Vonka V; Bubeník J; Bieblová J
Folia Biol (Praha); 2003; 49(6):217-22. PubMed ID: 14748435
[TBL] [Abstract][Full Text] [Related]
10. MHC class I down-regulation: tumour escape from immune surveillance? (review).
Bubeník J
Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
[TBL] [Abstract][Full Text] [Related]
11. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours.
Símová J; Bubeník J; Bieblová J; Rosalia RA; Fric J; Reinis M
Int J Oncol; 2006 Dec; 29(6):1567-71. PubMed ID: 17088998
[TBL] [Abstract][Full Text] [Related]
12. Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours.
Reinis M; Símová J; Indrová M; Bieblová J; Pribylová H; Moravcová S; Jandlová T; Bubeník J
Int J Oncol; 2007 Apr; 30(4):1011-7. PubMed ID: 17332942
[TBL] [Abstract][Full Text] [Related]
13. Tumour MHC class I downregulation and immunotherapy (Review).
Bubeník J
Oncol Rep; 2003; 10(6):2005-8. PubMed ID: 14534734
[TBL] [Abstract][Full Text] [Related]
14. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
Reinis M; Indrová M; Mendoza L; Mikysková R; Bieblová J; Bubeník J; Símová J
Int J Oncol; 2004 Oct; 25(4):1165-70. PubMed ID: 15375569
[TBL] [Abstract][Full Text] [Related]
15. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
16. High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress.
Byrne SN; Halliday GM
Cancer Immunol Immunother; 2003 Jun; 52(6):396-402. PubMed ID: 12739069
[TBL] [Abstract][Full Text] [Related]
17. Analysis of tumor progression by transcriptional profiling of mouse MK16 cell lines transformed with human papillomavirus type 16 E6 and E7 oncogenes and activated H-ras.
Smahel M; Smahelová J; Tejklová P; Tachezy R; Jelínek F
Oncol Rep; 2005 Dec; 14(6):1665-74. PubMed ID: 16273273
[TBL] [Abstract][Full Text] [Related]
18. CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
Reinis M; Símová J; Indrová M; Bieblová J; Bubeník J
Int J Oncol; 2007 May; 30(5):1247-51. PubMed ID: 17390028
[TBL] [Abstract][Full Text] [Related]
19. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells.
Lakatosová-Andelová M; Jinoch P; Dusková M; Marinov I; Vonka V
Int J Oncol; 2008 Jan; 32(1):265-71. PubMed ID: 18097567
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells.
Sobotková E; Dusková M; Smahel M; Holán V; Janousková O; Vonka V
Oncol Rep; 2004 Oct; 12(4):877-83. PubMed ID: 15375516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
